Buprenorphine Initiation for Opioid Use Disorder

(COPILOT Trial)

This trial aims to determine the best method for initiating buprenorphine treatment in individuals with opioid use disorder (OUD) who use fentanyl. It compares two approaches: a low-dose start and a direct-to-inject method. Researchers seek to evaluate how each approach impacts treatment retention and patient perceptions of symptoms and overall experience. Participants must have an OUD diagnosis, use fentanyl almost daily, and express interest in reducing or stopping fentanyl use. As a Phase 4 trial, this research explores how the already FDA-approved and effective treatment can benefit a broader range of patients.

The trial information does not specify if you need to stop taking your current medications. However, you cannot participate if you have a positive urine drug screening for methadone or buprenorphine at the start.

Research has shown that both long-acting injectable and sublingual buprenorphine treatments are generally safe for people with opioid use disorder (OUD).

Studies have found that long-acting injectable buprenorphine is well-tolerated, with no new safety concerns. The likelihood of experiencing opioid withdrawal symptoms or liver issues remains low. It has a strong safety record, with most side effects being mild, such as injection site reactions.

Sublingual buprenorphine is also safe, as supported by data from over 3,000 patients. Common side effects include mild issues like headaches and nausea. However, it effectively helps people stay in treatment, which is crucial for recovery.

Researchers are excited about these treatments for opioid use disorder because they offer new ways to administer buprenorphine. The Direct-to-inject (DTI) method delivers a long-acting injectable form of buprenorphine, like Brixadi or Sublocade, which can provide stable medication levels and reduce the need for daily dosing, making adherence easier. On the other hand, the Low-dose initiation (LDI) approach starts with a very low dose of sublingual buprenorphine and gradually increases it, which can help minimize withdrawal symptoms and improve comfort during the initial treatment phase. These approaches aim to enhance patient experience and increase the effectiveness of opioid addiction treatment.

This trial will compare two methods of buprenorphine initiation for opioid use disorder. Participants in one arm will receive long-acting injectable buprenorphine, which studies have shown to be effective for treating opioid use disorder (OUD). This treatment often reduces withdrawal symptoms and decreases opioid use. In one study, 75% of patients who received monthly injections remained drug-free a year later, indicating that the injections help maintain treatment adherence and reduce drug use.